Valuation: Structure Therapeutics Inc.

Market Cap 3.41B 2.97B 2.76B 2.54B 4.79B 326B 4.86B 32.57B 12.78B 162B 12.82B 12.54B 544B P/E 2026 *
-33.6x
P/E 2027 * -23.1x
Enterprise Value 2.41B 2.09B 1.95B 1.79B 3.38B 230B 3.43B 22.98B 9.02B 115B 9.05B 8.85B 384B EV / Sales 2026 *
62.6x
EV / Sales 2027 * 65,316x
Free-Float
76.06%
Yield 2026 *
-
Yield 2027 * -
1 day-2.89%
1 week-2.20%
1 month-10.12%
3 months+13.81%
6 months-46.53%
Current year-30.93%
1 week 46.4
Extreme 46.4
49.62
1 month 44.8
Extreme 44.8001
57.07
Current year 35.78
Extreme 35.78
94.77
1 year 15.8
Extreme 15.8
94.9
3 years 13.22
Extreme 13.22
94.9
5 years 13.22
Extreme 13.22
94.9
10 years 13.22
Extreme 13.22
94.9
Manager TitleAgeSince
Director of Finance/CFO 48 30/04/2022
Chief Executive Officer 62 30/04/2019
Chief Operating Officer 49 14/04/2026
Director TitleAgeSince
Director/Board Member 62 31/01/2019
Chairman 68 18/01/2022
Director/Board Member 66 28/03/2022
Date Insider Type Main position Quantity % Market Cap.
22/07/26
F-Prime Inc.
OtherCompany 17,452 0.0101%
22/07/26
F-Prime Inc.
OtherCompany 0 0%
14/07/26 Fiscal year

Chief Technology Officer

86,658 0.0620%
Change 5-day change 1-year change 3-year change Capi.($)
-2.89%-2.20%+173.11%+50.78% 3.41B
+2.35%+2.74%+38.10%+74.02% 56.54B
-0.21%-7.38%+27.52%+63.59% 53.6B
-2.44%+1.40%-15.61%-13.72% 22.91B
-2.85%-7.78%-9.28%+352.92% 21.37B
-0.41%-0.10%+23.70%-14.84% 20.27B
+0.79%-1.06%+33.99%-30.63% 17.56B
-2.48%-8.04%+16.82%+548.18% 14.75B
+3.41%-6.61%+162.81%+287.77% 13.53B
-5.25%-4.23%+42.32%+160.72% 13.33B
Average -0.98%-3.63%+49.35%+147.88% 23.73B
Weighted average by Cap. -0.24%-2.95%+32.69%+119.18%

Financials

2026 *2027 *
Net sales 38.46M 33.43M 31.12M 28.57M 53.96M 3.67B 54.79M 367M 144M 1.83B 144M 141M 6.13B 41.67K 36.22K 33.72K 30.96K 58.46K 3.98M 59.36K 397K 156K 1.98M 156K 153K 6.64M
Net income -288M -250M -233M -214M -403M -27.45B -410M -2.74B -1.08B -13.67B -1.08B -1.06B -45.83B -423M -368M -342M -314M -594M -40.39B -603M -4.04B -1.58B -20.11B -1.59B -1.55B -67.43B
Net Debt -1B -874M -813M -746M -1.41B -95.92B -1.43B -9.58B -3.76B -47.75B -3.77B -3.69B -160B -693M -602M -560M -515M -972M -66.12B -987M -6.61B -2.59B -32.92B -2.6B -2.54B -110B
Logo Structure Therapeutics Inc.
Structure Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing oral small molecule treatments for chronic metabolic and cardiopulmonary conditions with significant unmet medical needs. Its programs include Aleniglipron (GSBR-1290), ACCG-2671, GIP and GCG Receptor Oral Small Molecule Obesity Programs, ANPA-0073, and LTSE-2578. Its Aleniglipron is an oral and biased small molecule agonist of GLP-1R, a validated GPCR drug target for obesity. ACCG-2671 is an oral small molecule amylin receptor agonist for obesity. ANPA-0073 is a biased agonist targeting the apelin (APJ) receptor agonist. Its LTSE-2578, an Oral Small Molecule LPA1R Antagonist for IPF. It is developing an antagonist that targets lysophosphatidic acid 1 receptor (LPA1R), a GPCR implicated in responses to tissue injury and pro-fibrotic processes, for the treatment of IPF. It is developing oral incretins for potential combination therapy with GLP-1R or amylin candidates.
Employees
233
Date Price Change Volume
31/07/26 US$48.04 -2.89% 407,588
30/07/26 US$49.47 +4.48% 384,071
29/07/26 US$47.35 -1.13% 470,394
28/07/26 US$47.89 -1.64% 507,631
27/07/26 US$48.69 -0.88% 464,406
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
15
Last Close Price
48.04USD
Average target price
104.83USD
Spread / Average Target
+118.22%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. GPCR Stock